Abstract
Background and objective Cell-free DNA-based noninvasive prenatal testing (NIPT) has been validated as a screening test for certain fetal aneuploidy in high-risk women. High-risk indications include advanced maternal age (AMA), positive serum screen result, abnormal fetal ultrasound findings, and a previous affected pregnancy. However, recent studies show the effectiveness of NIPT in all pregnant women, regardless of risk. Determine if there are global differences in NIPT implementation between centers in Southeast Asia and the United States (US).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
